Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer
A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Colon
RATIONALE: Vitamin E may help prevent the development of cancer. Studying samples of tissue from patients with colorectal cancer who receive Vitamin E before undergoing surgery in the laboratory may help doctors learn more about how Vitamin E changes biomarkers related to colorectal cancer.
PURPOSE: This randomized early phase I trial is studying giving vitamin E supplements to see how it affects biomarkers in patients undergoing surgery for colorectal cancer.
調査の概要
詳細な説明
OBJECTIVES:
- Determine the effect of high γ-tocopherol vitamin E mixture supplementation on plasma levels of α-, γ-, and δ-tocopherols, and prostaglandin E_2 in patients planning to undergo surgery for colorectal cancer by comparing the blood samples collected before and after the supplementation in each of the groups and analyzing levels of tocopherols and their metabolites in urine samples.
- Test the hypothesis that the supplementation reduces oxidative and nitrosative stress by measuring plasma levels of F_2-isoprostane, C-reactive protein, and 3-nitrotyrosine as well as urinary levels of 8-hydroxy-2-deoxyguanosine (8-OHdG).
- Determine the levels of α-, γ-, and δ-tocopherols in colon tissues and analyze immunohistochemically for cell proliferation, apoptosis, β-catenin localization, RXR expression, cyclooxygenase-2, 8-OHdG, and 3-nitrotyrosine levels in colon cancer tissue slides.
OUTLINE: This is a multicenter study. The first 5 patients receive no supplements (to establish laboratory standards), all other patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive no intervention before undergoing planned surgery.
- Arm II: Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 1 week before undergoing planned surgery.
- Arm III: Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 2 weeks before undergoing planned surgery.
Blood and urine samples are collected at baseline and on the day of surgery for tocopherol and biomarker analysis. A sample of colon tissue is removed during standard surgical resection for chemical analysis. Plasma, tumor tissue, and nontumorous tissues are analyzed for levels of F_2-isoprostane, 8-OHdG, 3-nitrotyrosine, and prostaglandin E_2 via enzyme immunoassays and for levels of α-, γ-, and δ-tocopherols via HPLC.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
New Jersey
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
Suspected or confirmed colorectal cancer meeting the following criteria:
- Scheduled for surgery as the initial treatment
- Referred to the Cancer Institute of New Jersey or the Robert Wood Johnson University Hospital
- No requirement for urgent surgery (i.e., surgery that cannot wait for 2 weeks)
PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Negative pregnancy test
- Patients deemed in adequate health to undergo colon resection by their surgeon
- No uncontrolled diabetes, uncontrolled BP, chronic congestive heart failure, or history of renal insufficiency
- No personal or family history of bleeding disorders
- No known history of problems absorbing fats (e.g., Crohn disease, cystic fibrosis)
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior chemotherapy or radiotherapy for the treatment of this cancer
- More than 2 weeks since prior NSAIDs or corticosteroids
- No concurrent colestipol or orlistat
- No concurrent warfarin or dicumarol
No concurrent supplementation of vitamin E
- A multivitamin containing ≤ 60 IU vitamin E allowed
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし：Arm I
Patients receive no intervention before undergoing planned surgery.
|
|
|
実験的：Arm II
Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 1 week before undergoing planned surgery.
|
経口投与
All patients undergo biomarker analyses
|
|
実験的：Arm III
Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 2 weeks before undergoing planned surgery.
|
経口投与
All patients undergo biomarker analyses
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Plasma and urine levels of α-, γ-, and δ-tocopherols, and prostaglandin E2
時間枠：4 years
|
4 years
|
|
Plasma levels of F2-isoprostane, C-reactive protein, and 3-nitrotyrosine and urinary levels of 8-hydroxy-2-deoxyguanosine (8-OHdG)
時間枠：4 years
|
4 years
|
|
Presence in colon tissue of α-, γ-, and δ-tocopherols, cell proliferation and apoptosis indicators, β-catenin localization, RXR expression, and cyclooxygenase-2, 8-OHdG, and 3-nitrotyrosine levels
時間枠：4 years
|
4 years
|
協力者と研究者
捜査官
- 主任研究者：Susan Goodin, PharmD, FCCP, BCOP、Rutgers Cancer Institute of New Jersey
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
大腸がんの臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ
ビタミンEの臨床試験
-
University of Nevada, RenoUniversity of Nevada, Las Vegas完了
-
RWTH Aachen UniversityClinical Evaluation Research Unit at Kingston General Hospital引きこもった
-
Antoine FourréUniversiteit Antwerpen; University of Mons; University of Picardie Jules Verne完了
-
University of Alabama at Birminghamまだ募集していません
-
Yale UniversityNational Institute on Drug Abuse (NIDA)募集